The CRISPR market is projected to reach USD 7.1 billion by 2028 from USD 3.4 billion in 2023, at a CAGR of 15.6% during the forecast period. The key factors driving the growth of the global CRISPR market are growing demand for CRISPR-based gene therapies, growing advancements of CRISPR technology, and growing investment and funding from the government for CRISPR technology. However, the technical challenges associated with CRISPR technology are expected to restrain market growth to a certain extent.
The market for CRISPR is highly fragmented, with key players strategizing to capture majority of the market. Prominent players in the market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Genscript Biotech Corporation (China), CRISPR Therapeutics AG (Switzerland), Editas Medicine (US), Intellia Therapeutics, Inc. (US), Beam Therapeutics Inc. (US), Caribou Biosciences, Inc. (US), Lonza Group, Ltd. (Switzerland), Danaher Corporation (US), PerkinElmer, Inc. (US), Hera Biolabs (US), OriGene Technologies, Inc. (US), Cellecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), Twist Bioscience Corporation (US), Synthego Corporation (US), eGenesis (US), Inscripta, Inc. (US), and Precision BioSciences, Inc. (US).
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific, Inc. (US)
Thermo Fisher Scientific is one of the leading global providers of products and services for scientific research, manufacturing, and diagnostics. The company has a strong presence in the genome editing market, with a wide range of CRISPR-Cas9 products and services. Thermo Fisher's CRISPR products include enzymes, guide RNA, delivery systems, and analysis tools. The company also offers a variety of services related to CRISPR, such as consulting, training, and assay development.
Thermo Fisher is well positioned to benefit from the growing market for CRISPR technology. The company has been working on new products and services in the life sciences industry, and its CRISPR products and services are used by leading research institutions and pharmaceutical companies. Thermo Fisher is also investing heavily in the development of new CRISPR technologies, such as CRISPR-Cas13.
Merck KGaA (Germany)
Merck KGaA is a global science and technology company that has been at the forefront of CRISPR technology since its inception. The company owns a comprehensive portfolio of CRISPR and other advanced genomics technologies that impact the genome-editing process, from basic research to therapeutic delivery. Merck's CRISPR technology is used by researchers and scientists around the world to develop new treatments for a wide range of diseases, including cancer, sickle cell anemia, and HIV.
In addition to its leading CRISPR technology, Merck is also operational in the field of gene editing. The company has developed several novel gene editing technologies, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9). These technologies are used to make precise changes to DNA, which can be used to treat diseases, improve crops, or create new products. Merck is committed to advancing CRISPR technology and its applications in healthcare and agriculture. The company is investing heavily in research and development and is working with partners to bring CRISPR-based products to the market. Merck is also working to educate the public about CRISPR technology and its potential benefits.
Agilent Technologies, Inc. (US)
Agilent Technologies is a global leader in life sciences and diagnostics, with a strong focus on developing innovative tools and solutions for the research and development of CRISPR technology. The company offers a wide range of products and services that support all aspects of CRISPR research, from basic discovery to clinical translation. Agilent's CRISPR products include gene editing kits, sequencing instruments, and bioinformatics software. The company also provides training and consulting services to help researchers get the most out of CRISPR technology.
The company products and services are used by leading research institutions and pharmaceutical companies around the world. Agilent is also committed to advancing CRISPR technology for the benefit of human health. The company is currently working on several projects to develop CRISPR-based therapies for cancer, genetic diseases, and other conditions.
Genscript Biotech Corporation (China)
Genscript Biotech Corporation is a global biotechnology company that provides life sciences research and application products and services. The company has a strong focus on CRISPR technology and offers a wide range of products and services related to this cutting-edge gene editing technology.
The company's CRISPR technology is helping to accelerate the pace of research in a wide range of fields, including drug discovery, agriculture, and gene therapy. Genscript is a leading provider of CRISPR technology, and the company is well positioned to continue to grow in this rapidly expanding market. The company's strong focus on innovation, its global reach, and its commitment to customer service are all key factors that will help Genscript to maintain its leadership position in the CRISPR market.
CRISPR Market by Product (Enzymes, Kits, Libraries), Services (gRNA design, Cell Line Engineering, Screening), Application (Drug Discovery & Development, Agriculture), End User (Pharma, Biotech, CROs, Research Institutes) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE